Aura Biosciences appoints Jeremy Bender, Ph.D., M.B.A., to board of directors
Aura Biosciences expanded its board from six to seven directors and appointed Jeremy Bender as an independent Class II director effective July 7, 2026. The filing also discloses an amended director compensation policy, adopted June 11, 2026, that raised the equity awards for new and continuing non-employee directors.
Key points
- Jeremy Bender, Ph.D., M.B.A., is appointed to fill the newly created seat; his term expires at the 2029 annual meeting of stockholders.
- Dr. Bender joins the Compensation Committee and the Nominating and Corporate Governance Committee, effective July 7, 2026.
- His initial awards are a stock option for 60,000 shares and an RSU award for 30,000 shares, vesting in equal annual installments over three years.
- On June 11, 2026, the annual option award for continuing non-employee directors was raised from 17,000 to 30,000 shares, and the annual RSU award from 13,000 to 15,000 shares.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.